Browsing by Author "Coleman, C. Norman"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
    (Oxford, 2021-10) Prasanna, Pataje G.; Citrin, Deborah E.; Hildesheim, Jeffrey; Ahmed, Mansoor M.; Venkatachalam, Sundar; Riscuta, Gabriela; Xi, Dan; Zheng, Guangrong; van Deursen, Jan; Goronzy, Jorg; Kron, Stephen J.; Anscher, Mitchell S.; Sharpless, Norman E.; Campisi, Judith; Brown, Stephen L.; Niedernhofer, Laura J.; O’Loghlen, Ana; Georgakilas, Alexandros G.; Paris, Francois; Gius, David; Gewirtz, David A.; Schmitt, Clemens A.; Abazeed, Mohamed E.; Kirkland, James L.; Richmond, Ann; Romesser, Paul B.; Lowe, Scott W.; Gil, Jesus; Mendonca, Marc S.; Burma, Sandeep; Zhou, Daohong; Coleman, C. Norman; Radiation Oncology, School of Medicine
    Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.
  • Thumbnail Image
    Item
    Understanding High-Dose, Ultra-High Dose-Rate and , Spatially Fractionated Radiotherapy
    (Elsevier, 2020) Griffin, Robert J.; Ahmed, Mansoor M.; Amendola, Beatriz; Belyakov, Oleg; Bentzen, Søren M.; Butterworth, Karl T.; Chang, Sha; Coleman, C. Norman; Djonov, Valentin; Formenti, Sylvia C.; Glatstein, Eli; Guha, Chandan; Kalnicki, Shalom; Le, Quynh-Thu; Loo, Billy W., Jr.; Mahadevan, Anand; Massaccesi, Mariangela; Maxim, Peter G.; Mohiuddin, Majid; Mohiuddin, Mohammed; Mayr, Nina A.; Obcemea, Ceferino; Petersson, Kristoffer; Regine, William; Roach, Mack; Romanelli, Pantaleo; Simone, Charles B., II; Snider, James W.; Spitz, Douglas; Vikram, Bhadrasain; Vozenin, Marie-Catherine; Abdel-Wahab, May; Welsh, James; Wu, Xiaodong; Limoli, Charles L.; Radiation Oncology, School of Medicine
    The National Cancer Institute’s Radiation Research Program in collaboration with the Radiosurgery Society hosted a workshop on Understanding High-Dose, Ultra-High Dose rate and Spatially Fractionated Radiotherapy on August 20-21, 2018 to bring together experts in experimental and clinical experience in these and related fields. Critically, the overall aims were to understand the biological underpinning of these emerging techniques and the technical/physical parameters that must be further defined to drive clinical practice through innovative biologically-based clinical trials.
  • Thumbnail Image
    Item
    Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint
    (AACR, 2018-05) Ahmed, Mansoor M.; Coleman, C. Norman; Mendonca, Marc; Bentzen, Soren; Vikram, Bhadrasain; Seltzer, Stephen M.; Goodhead, Dudley; Obcemea, Ceferino; Mohan, Radhe; Prise, Kevin M.; Capala, Jacek; Citrin, Deborah; Kao, Gary; Aryankalayil, Molykutty; Eke, Iris; Buchsbaum, Jeffrey C.; Prasanna, Pataje G. S.; Liu, Fei-Fei; Le, Quynh-Thu; Teicher, Beverly; Kirsch, David G.; Smart, DeeDee; Tepper, Joel; Formenti, Silvia; Haas-Kogan, Daphne; Raben, David; Mitchell, James; Radiation Oncology, School of Medicine
    The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and there is evidence that the biological effects of radiation depend on dose size, schedule, and type of radiation. This National Cancer Institute (NCI)–sponsored workshop addressed the potential of using radiation-induced biological perturbations in addition to physical dose, Gy, as a transformational approach to quantifying radiation.